?Administration The purpose of the Mays Cancer Center (MCC) Research Administrative Division (MCC Administration) is to provide administrative leadership, oversight, and support for the research initiatives of the MCC membership; promote and coordinate the intra- and inter-programmatic transdisciplinary activities of this matrix-based Cancer Center within the University of Texas Health San Antonio (UT Health SA); and support a culture of collaboration and multi-institutional partnerships at the state and national levels. The MCC Administration seeks to facilitate and enhance scientific productivity and collaborations among members, and to translate the MCC Strategic Plan into action. MCC Administration provides operational leadership, organization, and financial oversight in support of the activities of the Director, Senior Leadership, Research Program Leaders, Shared Resources Directors, and all MCC members. As a matrix Cancer Center, MCC Administration provides support to 94 MCC members in three Research Programs from 18 departments in UT Health SA. MCC Administration leverages the expertise of its 16 centrally located Full Time Employees (FTE) to operate in an efficient and value-added manner in support of the mission of the Cancer Center. Areas of responsibility and functions of MCC Administration include management of: 1) strategic planning and evaluation activities; 2) MCC membership process; 3) faculty recruitment; 4) allocation of institutional funds, including Cancer Center-designated philanthropic funds ; 5) MCC Shared Resources; 6) MCC research seminars, symposia, and scientific program retreats; 7) space allocation; 8) pre-award management for complex cancer-relevant grant mechanisms; and 9) pre- and post-award management of the MCC internal Pilot Grant Program. Key accomplishments of the MCC Administration over the past five years include: ? Supporting strategic recruitment of 54 clinical and research faculty. Of these, 36 are full members ? Increasing direct cancer-relevant peer-reviewed research funding from $16.4M in 2014 to $27.9M in 2019 ? Developing strategic informatics solutions for reporting requirements and research purposes ? Implementing electronic reporting tools for essential data metrics for the Cancer Center ? Establishing the MCC Offices of Community Outreach and Engagement (COE) and Education. Future plans include: 1) continued administrative support for research initiatives, including submission of multi- investigator proposals. Examples are the upcoming submission of a Prostate Cancer SPORE and an American Cancer Society Institutional Research grant; 2) recruitments as laid out in the MCC Strategic Plan, 3) developing new resources such as the MCC Biobank; and 4) development of the next MCC Strategic Plan.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-25
Application #
10025085
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
25
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Yu, Xiaojie; Zhang, Yiqiang; Cavazos, David et al. (2018) miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis 9:193
Chen, Chen; Zhao, Shujie; Karnad, Anand et al. (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :

Showing the most recent 10 out of 989 publications